Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (101-110 of 199) with videos related to

Pageof 20
Sort By:
International Journal of Nanomedicine|January 8, 2015
Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenograftsJessica Sine, Cordula Urban, Derek Thayer, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesisMichael J Toneff, Zhijun Du, Jie Dong, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Cancer Research|September 23, 2003
Estrogen-mediated down-regulation of E-cadherin in breast cancer cellsSteffi Oesterreich, Wanleng Deng, Shiming Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivationAdrian V Lee, Rachel Schiff, Xiaojiang Cui, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|February 14, 2018
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to MetastasizeMario Giuliano, Anum Shaikh, Hin Ching Lo, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Pageof 20

Showing results (101-110 of 199) with videos related to

Sort By:
Pageof 20
International Journal of Nanomedicine|January 8, 2015
Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenograftsJessica Sine, Cordula Urban, Derek Thayer, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesisMichael J Toneff, Zhijun Du, Jie Dong, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Cancer Research|September 23, 2003
Estrogen-mediated down-regulation of E-cadherin in breast cancer cellsSteffi Oesterreich, Wanleng Deng, Shiming Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivationAdrian V Lee, Rachel Schiff, Xiaojiang Cui, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|February 14, 2018
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to MetastasizeMario Giuliano, Anum Shaikh, Hin Ching Lo, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Pageof 20